Teflaro

Teflaro is a brand name of ceftaroline, approved by the FDA in the following formulation(s):

TEFLARO (ceftaroline fosamil - powder; iv (infusion))

• 
  Manufacturer: CEREXA
  
  Approval date: October 29, 2010
  
  Strength(s): 400MG/VIAL, 600MG/VIAL ^[RLD]

Has a generic version of Teflaro been approved?

No. There is currently no therapeutically equivalent version of Teflaro available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Teflaro. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Phosphonocephem derivatives, process for the preparation of the same, and use thereof
  Patent 6,417,175
  Issued: July 9, 2002
  Inventor(s): Tomoyasu; Ishikawa & Shohei; Hashiguchi & Yuji; Iizawa
  Assignee(s): Takeda Chemical Industries, Ltd.
  A novel cephem compound of the formula: wherein R1 is a phosphono group or a group convertible to a phosphono group; R2 is a hydrogen atom or a group having a linkage through a carbon atom; each of Q and X is a nitrogen atom or CH; Y is S, O or CH2; n is 0 or 1; one of R3 and R4 is a pyridinium group which may be substituted and the other is a hydrogen atom or hydrocarbon group which may be substituted, or R3 and R4 taken together may form a quaternalized nitrogen-containing heterocyclic ring which may be substituted, or its ester or its salt, which has a superior anti-bacterial activity, stability, absorbability, etc., a production thereof and a pharmaceutical composition containing it, is provided.
  
  Patent expiration dates:
  
  
  • December 17, 2018
    
    ✓ 
    Patent use: METHOD OF TREATING BACTERIAL INFECTIONS
    ✓ 
    Drug substance
    ✓ 
    Drug product
  
  



• 
  Phosphonocephem compound
  Patent 6,906,055
  Issued: June 14, 2005
  Inventor(s): Ishikawa; Tomoyasu & Hashiguchi; Shohei & Iizawa; Yuji
  Assignee(s): Takeda Chemical Industries, Ltd.
  A cephem compound (particularly its crystal) represented by the formula [I], wherein X is CH3COOH, CH3CH2COOH or CH3CN, and n is 0 to 5, is useful as an antibacterial agent (particularly anti-MRSA agent) and shows superior quality such as high solid stability, possible long-term stable preservation and the like.
  
  Patent expiration dates:
  
  
  • December 15, 2021
    
    ✓ 
    Drug substance
    ✓ 
    Drug product
  
  



• 
  Phosphonocephem compound
  Patent 7,419,973
  Issued: September 2, 2008
  Inventor(s): Ishikawa; Tomoyasu & Hashiguchi; Shohei & Iizawa; Yuji
  Assignee(s): Takeda Pharmaceutical Company Limited
  A cephem compound (particularly its crystal) represented by the formula [I], wherein X is CH3COOH, CH3CH2COOH or CH3CN, and n is 0 to 5, is useful as an antibacterial agent (particularly anti-MRSA agent) and shows superior quality such as high solid stability, possible long-term stable preservation and the like.
  
  Patent expiration dates:
  
  
  • December 15, 2021
    
    ✓ 
    Drug product
  
  

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

• Exclusivity expiration dates:
  • October 29, 2015 - NEW CHEMICAL ENTITY
  
  

See also...

• Teflaro Consumer Information (Drugs.com)
• Teflaro Consumer Information (Wolters Kluwer)
• Teflaro Consumer Information (Cerner Multum)
• Teflaro Advanced Consumer Information (Micromedex)
• Teflaro AHFS DI Monographs (ASHP)
• Ceftaroline Consumer Information (Wolters Kluwer)
• Ceftaroline Consumer Information (Cerner Multum)
• Ceftaroline Intravenous Advanced Consumer Information (Micromedex)
• Ceftaroline Fosamil AHFS DI Monographs (ASHP)